Physician profile
Edgar Stanley
NPI 1184688624
$6,836.79
in general payments reported to CMS, 2019-2025
38 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $500 · 2021: $882 · 2022: $1,043 · 2023: $1,094 · 2024: $1,448 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,744.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $871.89 | 2019-2025 | |
| Amgen INC. | $726.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $647.01 | 2021-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $421.80 | 2019-2025 | Pifeltro |
| Glaxosmithkline, LLC. | $379.19 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $320.51 | 2019-2025 | |
| Lilly USA, LLC | $303.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.01 | 2021-2025 | Jardiance, Tradjenta |
| Kowa Pharmaceuticals America, INC. | $251.49 | 2020-2022 | |
| Amarin Pharma, INC. | $251.03 | 2019-2021 | |
| Viiv Healthcare Company | $240.19 | 2020-2025 | Apretude, Dovato |
| Boston Scientific Corporation | $196.90 | 2019-2023 | Watchman |
| Abbvie INC. | $192.71 | 2020-2024 | Ubrelvy |
| Novo Nordisk INC | $190.76 | 2020-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $182.56 | 2021-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $169.24 | 2020-2025 | Nexletol |
| Abbott Laboratories | $155.90 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Intuitive Surgical, INC. | $153.09 | 2024 | |
| Phathom Pharmaceuticals, INC. | $119.63 | 2023-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $95.61 | 2019-2025 | Spravato |
| Seqirus USA INC | $87.69 | 2022-2024 | Flucelvax Quadrivalent, Fluad Quadrivalent, Fluad |
| Idorsia Pharmaceuticals US INC | $84.97 | 2023-2024 | Quviviq |
| Sanofi Pasteur INC. | $80.38 | 2019-2024 | |
| Astellas Pharma US INC | $78.41 | 2023-2025 | Veozah |
| Erbe USA INC | $50.00 | 2024 | |
| Janssen Biotech, INC. | $43.68 | 2023 | Symtuza |
| Otsuka America Pharmaceutical, INC. | $42.27 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $28.50 | 2020 | |
| Hologic Sales and Service, LLC | $27.25 | 2022-2025 | Aptima |
| Si-Bone, INC. | $23.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.84 | 2022 | |
| Edwards Lifesciences Corporation | $21.20 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Corcept Therapeutics | $20.27 | 2021 | |
| Shield Therapeutics INC | $17.71 | 2024 | |
| Tolmar, INC. | $16.09 | 2024 | |
| Emd Serono, INC. | $14.74 | 2019 | |
| Assertio Therapeutics, INC. | $13.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Stanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.